含微生态制剂的四联疗法治疗初治失败的幽门螺杆菌感染31例  

Effect of Quadruple Therapy Containing Microecologics on Helicobacter Pylori Infection after First Treatment Failure in 31 Cases

作　　者：周刚[1] 李之印[1] 王仲略[1] 沈慧琳 

机构地区：[1]浙江省杭州市第二人民医院,浙江杭州310005

出　　处：《中国药业》2011年第9期58-59,共2页China Pharmaceuticals

基　　金：浙江省自然科学基金项目;项目编号:Y2080675

摘　　要：目的观察含微生态制剂的四联疗法治疗初治失败的幽门螺杆菌感染的疗效和不良反应。方法将62例幽门螺杆菌根除失败的患者随机均分为两组,A组予雷贝拉唑+呋喃唑酮+阿莫西林+胶体果胶铋,B组予雷贝拉唑+呋喃唑酮+阿莫西林+微生态制剂,疗程均为7 d,治疗结束4周后复查14C-尿素呼气试验,判断是否根除幽门螺杆菌。结果 A组和B组幽门螺杆菌根除率分别为79.31%和83.33%(P>0.05);B组胃肠道不良反应少于A组(P<0.05)。结论含微生态制剂的四联疗法能有效根除初治失败的幽门螺杆菌感染,且能够显著降低治疗过程中的胃肠道不良反应。Objective To observe the effects and adverse reactions of quadruple therapy with microecologics supplementation on Helicobacter pylori（HP） infection after first treatment failure.Methods Sixty-two cases of HP eradication failure were divided into two groups randomly,group A treated with rabeprazole＋furazolidone＋amoxillin＋colloidal bismuth pectin and group B with rabeprazole＋furazolidone＋amoxicillin＋microecologics,the treatment course was 7 d in both groups.The eradication of HP was redetermined by the 14C-urea breath test in 4 weeks after treatment.Results The eradication rate was 79.31% in group A and 83.33% in group B respectively（P0.05）.The gastrointestinal adverse reactions in group B were fewer than those in group A（P0.05）.Conclusion The quadruple therapy containing microecologics is effective in HP infection eradication after first treatment failure,furthermore,which may obviously reduce the adverse reactions in the treatment course.

关 键 词：微生态制剂 幽门螺杆菌 四联疗法 

分 类 号：R969.4[医药卫生—药理学] R975[医药卫生—药学]